{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:59:09Z","timestamp":1789520349562,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Zur Therapie der chronischen Hepatitis-B-Virus-(HBV-)Infektion stehen aktuell pegyliertes Interferon-Alpha und Nucleosid\u2011\/Nucleotidanaloga (Entecavir und Tenofovir) zur Verf\u00fcgung. Diese Medikamente erm\u00f6glichen eine Virussuppression und eine Normalisierung des Leberenzyms Glutamat-Pyruvat-Transaminase (GPT) und verhindern ein Fortschreiten der Lebererkrankung. Zahlreiche noch in klinischer Entwicklung befindliche Therapiestrategien haben jedoch eine funktionelle Heilung zum Ziel. Dabei soll erreicht werden, dass das HBV-H\u00fcllprotein HBsAg im Blutserum nicht mehr nachweisbar ist (\u201eausgeheilte\u201c Hepatitis\u00a0B). Der vorliegende Beitrag gibt eine \u00dcbersicht \u00fcber aktuelle und m\u00f6gliche zuk\u00fcnftige antivirale Therapien gegen die chronische HBV-Infektion. Als Grundlage diente eine Literaturrecherche unter besonderer Ber\u00fccksichtigung der aktuellen Leitlinien sowie aktueller Kongressbeitr\u00e4ge.<\/jats:p><jats:p>Die aktuell verf\u00fcgbaren antiviralen Therapien f\u00fchren nur sehr selten zur Elimination von HBsAg (funktionelle Heilung). Auch ist bisher weitgehend unklar, bei welchen Patienten ein Absetzen der Langzeittherapie mit Entecavir bzw. Tenofovir sinnvoll ist. Neue Therapiestrategien in klinischer Entwicklung f\u00fchren bei einem h\u00f6heren Anteil der Patienten zur funktionellen Heilung. Wahrscheinlich ist aber eine Kombination mehrerer antiviraler Strategien erforderlich, um die funktionelle Heilung f\u00fcr die Mehrheit der Patienten zu erreichen. Eine solche Therapie kann voraussichtlich in den n\u00e4chsten 5\u201310\u00a0Jahren vorliegen.<\/jats:p>","DOI":"10.1007\/s00103-021-03483-x","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T14:10:45Z","timestamp":1642083045000},"page":"238-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chronische Hepatitis-B-Virusinfektion: aktuelle und zuk\u00fcnftige Therapieans\u00e4tze","Chronic hepatitis\u00a0B virus infection: current and future treatment strategies"],"prefix":"10.1007","volume":"65","author":[{"given":"Christoph","family":"Neumann-Haefelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thimme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"3483_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway\u00a0JD, Flaxman\u00a0AD, Naghavi\u00a0M et\u00a0al (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388:1081\u20131088","journal-title":"Lancet"},{"key":"3483_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/a-1498-2512","volume":"59","author":"M Cornberg","year":"2021","unstructured":"Cornberg\u00a0M, Sandmann\u00a0L, Protzer\u00a0U et al (2021) S3-Leitlinie der Deutschen Gesellschaft fur Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion (AWMF-Register-Nr.\u00a0021-11). Z\u00a0Gastroenterol 59:691\u2013776","journal-title":"Z Gastroenterol"},{"key":"3483_CR3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang\u00a0TT, Liaw\u00a0YF, Wu\u00a0SS et al (2010) Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52:886\u2013893","journal-title":"Hepatology"},{"key":"3483_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin\u00a0P, Gane\u00a0E, Buti\u00a0M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a\u00a05-year open-label follow-up study. Lancet 381:468\u2013475","journal-title":"Lancet"},{"key":"3483_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J\u00a0Hepatol 67:370\u2013398","journal-title":"J Hepatol"},{"key":"3483_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti\u00a0M, Gane\u00a0E, Seto\u00a0WK et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a\u00a0randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1:196\u2013206","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3483_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/hep.31793","volume":"74","author":"H Toyoda","year":"2021","unstructured":"Toyoda\u00a0H, Leong\u00a0J, Landis\u00a0C et\u00a0al (2021) Treatment and renal outcomes up to 96\u00a0weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice. Hepatology 74:656\u2013666","journal-title":"Hepatology"},{"key":"3483_CR8","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/hep.29320","volume":"66","author":"GV Papatheodoridis","year":"2017","unstructured":"Papatheodoridis\u00a0GV, Idilman\u00a0R, Dalekos\u00a0GN et\u00a0al (2017) The risk of hepatocellular carcinoma decreases after the first 5\u00a0years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 66:1444\u20131453","journal-title":"Hepatology"},{"key":"3483_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi\u00a0J, Kim\u00a0HJ, Lee\u00a0J et\u00a0al (2019) Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a\u00a0Korean nationwide cohort study. JAMA Oncol 5:30\u201336","journal-title":"JAMA Oncol"},{"key":"3483_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","volume":"19","author":"WM Choi","year":"2021","unstructured":"Choi\u00a0WM, Choi\u00a0J, Lim\u00a0YS (2021) Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a\u00a0systematic review and meta-analysis. Clin Gastroenterol Hepatol 19:246\u2013258.e9","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3483_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","volume":"158","author":"TC Yip","year":"2020","unstructured":"Yip\u00a0TC, Wong\u00a0VW, Chan\u00a0HL et\u00a0al (2020) Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology 158:215\u2013225","journal-title":"Gastroenterology"},{"key":"3483_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","volume":"69","author":"SW Lee","year":"2020","unstructured":"Lee\u00a0SW, Kwon\u00a0JH, Lee\u00a0HL et al (2020) Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a\u00a0large-scale, propensity score analysis. Gut 69:1301\u20131308","journal-title":"Gut"},{"key":"3483_CR13","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/jvh.13572","volume":"28","author":"JE Na","year":"2021","unstructured":"Na\u00a0JE, Sinn\u00a0DH, Lee\u00a0JH et\u00a0al (2021) Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J\u00a0Viral Hepat 28:1392\u20131399","journal-title":"J Viral Hepat"},{"key":"3483_CR14","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/apt.16197","volume":"53","author":"S Pol","year":"2021","unstructured":"Pol\u00a0S (2021) Similar 5\u2011year HCC occurrence in tenofovir- and entecavir-treated HBV chronic infection in the French AFEF\/ANRS CO22 Hepather cohort. Aliment Pharmacol Ther 53:616\u2013629","journal-title":"Aliment Pharmacol Ther"},{"key":"3483_CR15","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/S0168-8278(20)30755-8","volume":"73","author":"F van B\u00f6mmel","year":"2021","unstructured":"van B\u00f6mmel\u00a0F, Stein\u00a0K, Heyne\u00a0R et al (2021) Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: results of the Stop-NUC trial. J\u00a0Hepatol 73:S118","journal-title":"J Hepatol"},{"key":"3483_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jhep.2021.04.040","volume":"75","author":"T Berg","year":"2021","unstructured":"Berg\u00a0T, Lampertico\u00a0P (2021) The times they are a\u2011changing\u2014a refined proposal for finite HBV nucleos(t)ide analogue therapy. J\u00a0Hepatol 75:474\u2013480","journal-title":"J Hepatol"},{"key":"3483_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1708131","volume":"378","author":"G Jourdain","year":"2018","unstructured":"Jourdain\u00a0G, Ngo-Giang-Huong\u00a0N, Harrison\u00a0L et al (2018) Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N\u00a0Engl J Med 378:911\u2013923","journal-title":"N Engl J Med"},{"key":"3483_CR18","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","volume":"374","author":"CQ Pan","year":"2016","unstructured":"Pan\u00a0CQ, Duan\u00a0Z, Dai\u00a0E et\u00a0al (2016) Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N\u00a0Engl J Med 374:2324\u20132334","journal-title":"N Engl J Med"},{"key":"3483_CR19","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/hep.31610","volume":"73","author":"J Choi","year":"2021","unstructured":"Choi\u00a0J, Yoo\u00a0S, Lim\u00a0YS (2021) Comparison of long-term clinical outcomes between spontaneous and therapy-induced HBsAg seroclearance. Hepatology 73:2155\u20132166","journal-title":"Hepatology"},{"key":"3483_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/a-0824-1576","volume":"57","author":"R Bartenschlager","year":"2019","unstructured":"Bartenschlager\u00a0R, Urban\u00a0S, Protzer\u00a0U (2019) Towards curative therapy of chronic viral hepatitis. Z\u00a0Gastroenterol 57:61\u201373","journal-title":"Z Gastroenterol"},{"key":"3483_CR21","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1111\/liv.14851","volume":"41","author":"AA Roca Suarez","year":"2021","unstructured":"Roca Suarez\u00a0AA, Testoni\u00a0B, Zoulim\u00a0F (2021) HBV 2021: new therapeutic strategies against an old foe. Liver Int 41:S15\u2013S23","journal-title":"Liver Int"},{"key":"3483_CR22","doi-asserted-by":"publisher","first-page":"E81","DOI":"10.1016\/S0618-8278(19)30141-0","volume":"70","author":"H Wedemeyer","year":"2019","unstructured":"Wedemeyer\u00a0H, Schoneweis\u00a0K, Bogomolov\u00a0PO et al (2019) Final results of a\u00a0multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon alpha 2a in patients with chronic HBV\/HDV co-infection. J\u00a0Hepatol 70:E81","journal-title":"J Hepatol"},{"key":"3483_CR23","first-page":"S291","volume":"75","author":"T Asselah","year":"2021","unstructured":"Asselah\u00a0T, Arama\u00a0SS, Bogomolov\u00a0P et al (2021) Safety and efficacy of bulevirtide monotherapy and in combination withpPeginterferon alfa-2a in patients with chronic hepatitis delta: 24\u00a0weeks interim data of MYR204 phase 2b study. J\u00a0Hepatol 75:S291","journal-title":"J Hepatol"},{"key":"3483_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","volume":"159","author":"F Zoulim","year":"2020","unstructured":"Zoulim\u00a0F, Lenz\u00a0O, Vandenbossche\u00a0JJ et al (2020) JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a\u00a0phase 1\u00a0study of patients with chronic infection. Gastroenterology 159:521\u2013533","journal-title":"Gastroenterology"},{"key":"3483_CR25","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","volume":"158","author":"M Bazinet","year":"2020","unstructured":"Bazinet\u00a0M, Pantea\u00a0V, Placinta\u00a0G et al (2020) Safety and efficacy of 48\u00a0weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy. Gastroenterology 158:2180\u20132194","journal-title":"Gastroenterology"},{"key":"3483_CR26","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S0168-8278(20)30597-3","volume":"73","author":"E Gane","year":"2020","unstructured":"Gane\u00a0E, Locarnini\u00a0S, Lim\u00a0T et al (2020) Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. J\u00a0Hepatol 73:S20","journal-title":"J Hepatol"},{"key":"3483_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12072-018-9912-8","volume":"13","author":"J Lang","year":"2019","unstructured":"Lang\u00a0J, Neumann-Haefelin\u00a0C, Thimme\u00a0R (2019) Immunological cure of HBV infection. Hepatol Int 13:113\u2013124","journal-title":"Hepatol Int"},{"key":"3483_CR28","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/gutjnl-2020-322404","volume":"70","author":"K Heim","year":"2020","unstructured":"Heim\u00a0K, Binder\u00a0B, Sagar et\u00a0al (2020) TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection. Gut 70:1550\u20131560","journal-title":"Gut"},{"key":"3483_CR29","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1002\/hep.31795","volume":"74","author":"EJ Gane","year":"2021","unstructured":"Gane\u00a0EJ, Kim\u00a0HJ, Visvanathan\u00a0K et\u00a0al (2021) Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B. Hepatology 74:1737\u20131749","journal-title":"Hepatology"},{"key":"3483_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","volume":"157","author":"C Boni","year":"2019","unstructured":"Boni\u00a0C, Janssen\u00a0HLA, Rossi\u00a0M et al (2019) Combined GS-4774 and tenofovir therapy can improve HBV-specific T\u2011cell responses in patients with chronic hepatitis. Gastroenterology 157:227\u2013241","journal-title":"Gastroenterology"},{"key":"3483_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","volume":"16","author":"F Zoulim","year":"2020","unstructured":"Zoulim\u00a0F, Fournier\u00a0C, Habersetzer\u00a0F et al (2020) Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a\u00a0phase 1b placebo-controlled trial. Hum Vaccin Immunother 16:388\u2013399","journal-title":"Hum Vaccin Immunother"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03483-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-021-03483-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03483-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T20:26:06Z","timestamp":1700079966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-021-03483-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3483"],"URL":"https:\/\/doi.org\/10.1007\/s00103-021-03483-x","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Neumann-Haefelin ist als Referent f\u00fcr die Firmen Gilead Sciences, Merck Sharp & Dohme, Pfizer sowie die Falk Foundation e.\u202fV. t\u00e4tig. Zudem \u00fcbernimmt er redaktionelle T\u00e4tigkeiten f\u00fcr die Falk Foundation. R.\u00a0Thimme ist als Referent f\u00fcr die Firma Bayer Vital und die Falk Foundation sowie als Berater f\u00fcr die Firmen AbbVie, Gilead Sciences, OPASCA, Topas Therapeutics und Roche t\u00e4tig. Zudem \u00fcbernimmt er redaktionelle T\u00e4tigkeiten f\u00fcr die Falk Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}